How does Donanemab compare to other Alzheimer's drugs? | Morning in America
July 18, 2023
814
14
6
2.46%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Newsnation Episodes Around July 18, 2023
See what was published immediately before and after this episode.
4:18Now PlayingHow does Donanemab compare to other Alzheimer's drugs? | Morning in America
YouTube Description
as posted by the channelEli Lilly and Co. is seeking FDA approval for Donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease. Dr. Ian Smith weighs out the pros and cons of this drug's ability to slow Alzheimer's.
Watch #MorningInAmerica
#Alzheimers #FDA #Donanemab
Start your day with "Morning in America," NewsNation's live three-hour national morning newscast hosted by Adrienne Bankert. Weekdays starting at 7a/6C. #MorningInAmerica
NewsNation is your source for fact-based, unbiased news for all America.
More from NewsNation
Get our app
Find us on cable
How to watch on TV or streaming
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.